These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 30827246)
1. An Overview on the Potential Antimycobacterial Agents Targeting Serine/Threonine Protein Kinases from Mycobacterium tuberculosis. Mori M; Sammartino JC; Costantino L; Gelain A; Meneghetti F; Villa S; Chiarelli LR Curr Top Med Chem; 2019; 19(9):646-661. PubMed ID: 30827246 [TBL] [Abstract][Full Text] [Related]
2. Targeting the messengers: Serine/threonine protein kinases as potential targets for antimycobacterial drug development. Khan MZ; Kaur P; Nandicoori VK IUBMB Life; 2018 Sep; 70(9):889-904. PubMed ID: 29934969 [TBL] [Abstract][Full Text] [Related]
3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Tomioka H Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755 [TBL] [Abstract][Full Text] [Related]
4. Investigating the inhibitory potential of 2-Aminopurine metal complexes against serine/threonine protein kinases from Mycobacterium tuberculosis. Bais VS; Mohapatra B; Ahamad N; Boggaram S; Verma S; Prakash B Tuberculosis (Edinb); 2018 Jan; 108():47-55. PubMed ID: 29523327 [TBL] [Abstract][Full Text] [Related]
5. A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling. Székely R; Wáczek F; Szabadkai I; Németh G; Hegymegi-Barakonyi B; Eros D; Szokol B; Pató J; Hafenbradl D; Satchell J; Saint-Joanis B; Cole ST; Orfi L; Klebl BM; Kéri G Immunol Lett; 2008 Mar; 116(2):225-31. PubMed ID: 18258308 [TBL] [Abstract][Full Text] [Related]
6. NU-6027 Inhibits Growth of Mycobacterium tuberculosis by Targeting Protein Kinase D and Protein Kinase G. Kidwai S; Bouzeyen R; Chakraborti S; Khare N; Das S; Priya Gosain T; Behura A; Meena CL; Dhiman R; Essafi M; Bajaj A; Saini DK; Srinivasan N; Mahajan D; Singh R Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285226 [TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
8. Sclerotiorin inhibits protein kinase G from Mycobacterium tuberculosis and impairs mycobacterial growth in macrophages. Chen D; Ma S; He L; Yuan P; She Z; Lu Y Tuberculosis (Edinb); 2017 Mar; 103():37-43. PubMed ID: 28237032 [TBL] [Abstract][Full Text] [Related]
9. Leads for antitubercular compounds from kinase inhibitor library screens. Magnet S; Hartkoorn RC; Székely R; Pató J; Triccas JA; Schneider P; Szántai-Kis C; Orfi L; Chambon M; Banfi D; Bueno M; Turcatti G; Kéri G; Cole ST Tuberculosis (Edinb); 2010 Nov; 90(6):354-60. PubMed ID: 20934382 [TBL] [Abstract][Full Text] [Related]
10. [Prospects for development of new antituberculous drugs]. Tomioka H Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850 [TBL] [Abstract][Full Text] [Related]
11. Multisystem Analysis of Carette X; Platig J; Young DC; Helmel M; Young AT; Wang Z; Potluri LP; Moody CS; Zeng J; Prisic S; Paulson JN; Muntel J; Madduri AVR; Velarde J; Mayfield JA; Locher C; Wang T; Quackenbush J; Rhee KY; Moody DB; Steen H; Husson RN mBio; 2018 Mar; 9(2):. PubMed ID: 29511081 [TBL] [Abstract][Full Text] [Related]
12. [Development and study of structure-activity relationship of drugs against Mycobacterium tuberculosis]. Baska F; Székely ER; Szántai-Kis C; Bánhegyi P; Hegymegi-Barakonyi B; Németh G; Breza N; Zsákai L; Greff Z; Pató J; Kéri G; Orfi L Acta Pharm Hung; 2013; 83(3):88-95. PubMed ID: 24369587 [TBL] [Abstract][Full Text] [Related]